Effect of myocardial dysfunction in cardiac morbidity and all cause mortality in childhood cancer subjects treated with anthracycline therapy.

Toro-Salazar, Olga H; Gillan, Eileen; Ferranti, Joanna; Orsey, Andrea; Rubin, Karen; Upadhyay, Shailendra; Mazur, Wojciech; Hor, Kan N

Toro-Salazar, Olga H; Gillan, Eileen; Ferranti, Joanna; Orsey, Andrea; Rubin, Karen; Upadhyay, Shailendra; Mazur, Wojciech; Hor, Kan N.

Afiliación

Toro-Salazar OH; Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA. otoro@connecticutchildrens.org.
Gillan E; Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
Ferranti J; Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
Orsey A; Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
Rubin K; Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
Upadhyay S; Connecticut Children's Medical Center, 282 Washington Street, Hartford, CT, 06106, USA.
Mazur W; Ohio Heart and Vascular Center, The Christ Hospital, Cincinnati, OH, USA.
Hor KN; Nationwide Children's Hospital, Columbus, OH, USA.

Cardiooncology ; 1(1): 1, 2015 Nov 26.

Article en En | MEDLINE | ID: mdl-33530141

Palabras clave

Anthracyclines; Cardiomyopathy; Cardiotoxicity

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Tipo de estudio: Prognostic_studies / Risk_factors_studies Idioma: En Revista: Cardiooncology Año: 2015 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google